Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Four year follow up report of the InnFocus microshunt in the surgical management of glaucoma

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Glaucoma II

Session Date/Time: Tuesday 08/09/2015 | 08:00-10:30

Paper Time: 09:54

Venue: Room 17

First Author: : J.Batlle DOMINICAN REPUBLIC

Co Author(s): :                        

Abstract Details

Purpose:

To determine the safety and efficacy of the InnFocus Microshunt used in the surgical treatment of patients that are resistant to medical therapy and require surgical management of their glaucoma.

Setting:

All 23 patients were operated after being properly counseled and consented with a protocol approved by the National Bioethics Committee in Santo Domingo. The surgery was performed by the author at Centro Laser.

Methods:

23 patients with an average IOP of 23.8 mmHg under maximal medical therapy were chosen to receive implantation of the new microshunt made of the novel SBS polymer which is relatively anergic. The patients were all operated under topical anesthesia and the surgery preceded by a three minute application of Mitomycin C at 0.4mg/ml concentration. The patients were carefully followed for the next four years.

Results:

The average IOP after four years was 10.3 mmHg without treatment. At two years the success rate was 100% with only one patient requiring treatment with one drop. At four years, three of the blebs failed but the average IOP remained at 10.5 mmHg. The main complication was transient hypotony in the first week after surgery in six patients and delayed bleb failure at four years in 3 patients

Conclusions:

This study has proven that the InnFocus Microshunt is safe and effective in the surgical management of glaucoma with outstanding record of IOP reduction and relatively minor side effects.

Financial Interest:

NONE

Back to previous